Key Takeaways
- Two phase 3 clinical trials involving 916 adults found that an experimental oral medication called povorcitinib improved skin pigmentation in people with moderate-to-severe nonsegmental vitiligo.
- After 52 weeks, 18.9% of patients receiving povorcitinib achieved at least 75% improvement in facial vitiligo in each trial, compared with 6.8% and 3.1% in the respective placebo groups.
- The drug also improved pigmentation across the body, although only about 2% to 3% of treated patients achieved at least 75% whole-body improvement.
- Exploratory analyses indicated that povorcitinib might also help stabilize vitiligo and reduce the development or expansion of patches.
- Safety remains important. Four treated patients developed basal cell carcinoma, and one experienced blood-clotting complications.
- Other oral treatments, including upadacitinib, are advancing through clinical research, suggesting that treatment options for widespread vitiligo may expand.
Introduction
Vitiligo causes areas of skin to lose pigmentation. New clinical trials are investigating oral medications that may help restore skin color in people with widespread vitiligo.
For someone living with vitiligo, watching white patches gradually spread across the face, hands, or body can be frustrating. Treatment often takes months, and even when it works, the return of skin pigmentation may be incomplete.
Until recently, options specifically developed to restore pigmentation were limited. Most treatments involved applying medication directly to affected skin, undergoing light therapy, or combining several approaches.
Now, two large clinical trials suggest that an oral medication could offer another possibility, particularly for people whose vitiligo affects extensive areas of the body.
The research, published in Nature Medicine, found that povorcitinib, an experimental medication that blocks a specific immune signaling pathway, produced significantly greater repigmentation than placebo after one year.
The results are encouraging, but they also reveal the challenges that remain. Most patients did not achieve the trials’ primary response target, and the potential risks of long-term immune-modifying treatment require careful evaluation.
For people with vitiligo, the importance of this research extends beyond one drug. It adds to growing evidence that treatments targeting the immune processes responsible for pigment loss may change how the condition is managed.
What Is Vitiligo, and Why Does It Happen?
Vitiligo is a chronic autoimmune condition that causes patches of skin to lose their natural color.
Skin pigmentation comes from cells called melanocytes, which produce melanin. In people with vitiligo, the immune system mistakenly attacks these pigment-producing cells.
As melanocytes are damaged or destroyed, affected areas gradually become lighter or completely white.
Vitiligo can develop at any age and affect any skin tone. It is not contagious and does not result from poor hygiene.
The condition has two main forms.
Nonsegmental vitiligo, the most common type, generally causes patches on both sides of the body. These may appear on the face, hands, arms, legs, trunk, and around body openings.
Segmental vitiligo usually affects one side or a particular region of the body and often follows a different pattern of progression.
The new povorcitinib trials focused exclusively on adults with nonsegmental vitiligo.
Vitiligo Affects More Than Skin Color
Although vitiligo does not usually cause physical pain, its effects can extend beyond changes in appearance.
Visible patches, particularly on the face and hands, may affect confidence, social interactions, and emotional well-being.
Some people experience anxiety, depression, or distress related to unwanted attention and stigma.
Vitiligo is also associated with other autoimmune conditions, particularly autoimmune thyroid disorders.
Not everyone with vitiligo wants treatment to restore pigmentation. Some people are comfortable with their appearance, while others consider repigmentation an important personal goal.
Treatment decisions should reflect the individual’s preferences, the extent of the condition, and the potential benefits and risks.
How the New Oral Medication Works
Povorcitinib belongs to a class of medications called Janus kinase inhibitors, commonly known as JAK inhibitors.
These medications interfere with signaling pathways that help regulate immune activity.
In vitiligo, immune cells release inflammatory signals that contribute to the destruction of melanocytes.
One important pathway involves interferon-gamma, JAK signaling, and a protein called CXCL10, which helps recruit immune cells involved in pigment-cell damage.
Povorcitinib selectively inhibits JAK1, a component of this inflammatory signaling process.
By reducing this activity, the medication may help create conditions in which surviving melanocytes, or pigment-producing cells originating from hair follicles, can restore pigmentation.
Unlike a cream applied to individual patches, an oral medication acts throughout the body.
That distinction could be particularly important for people with extensive vitiligo, although systemic treatment also exposes the body to potentially greater risks.
What the Two Phase 3 Trials Examined
The study published in Nature Medicine (Ezzedine et al., 2026) reported the results of two similarly designed clinical trials called STOP-V1 and STOP-V2.
Together, they enrolled 916 adults with moderate-to-severe nonsegmental vitiligo.
STOP-V1 included 467 participants, while STOP-V2 included 449.
All participants had vitiligo affecting the face and at least 5% of their total body surface area.
Patients were randomly assigned to receive either 30 milligrams of oral povorcitinib or placebo once daily.
Neither the participants nor the investigators knew which treatment had been assigned during the 52-week comparison period.
The researchers evaluated changes in pigmentation using the Vitiligo Area Scoring Index, a measurement that considers the extent and severity of depigmentation.
Their primary outcome was the proportion of patients achieving at least 75% improvement in facial vitiligo after 52 weeks.
This represented a substantial reduction in facial depigmentation, not complete disappearance of vitiligo.
What Researchers Found
Nearly One in Five Treated Patients Achieved Major Facial Improvement
Both STOP-V1 and STOP-V2 met their primary endpoint after 52 weeks of treatment.
In STOP-V1, 18.9% of patients receiving povorcitinib achieved at least a 75% improvement in their facial Vitiligo Area Scoring Index (F-VASI75), compared with 6.8% receiving placebo. The difference was statistically significant (P = 0.0003).
STOP-V2 independently produced the same 18.9% response rate among povorcitinib-treated patients, compared with 3.1% in the placebo group (P < 0.0001).
These findings indicate that the medication can produce substantial facial repigmentation in some adults with moderate-to-severe nonsegmental vitiligo.
However, approximately four in five treated participants did not achieve this level of improvement after one year.
That does not necessarily mean they experienced no benefit. The F-VASI75 endpoint measures a substantial reduction in facial depigmentation, and patients who did not reach that threshold may still have experienced smaller improvements.
Importantly, a 75% improvement in the facial vitiligo score does not mean complete restoration of normal skin pigmentation.
Whole-Body Repigmentation Also Improved
Povorcitinib improved pigmentation beyond the face, although substantial repigmentation across the entire body remained difficult to achieve.
In STOP-V1, 18.4% of patients receiving povorcitinib achieved at least a 50% improvement in their total-body Vitiligo Area Scoring Index (T-VASI50), compared with 6.5% receiving placebo.
In STOP-V2, the corresponding figures were 12.9% and 4.8%.
Both differences were statistically significant.
Average total-body vitiligo scores improved by 24.1% in STOP-V1 and 21.1% in STOP-V2 among patients receiving povorcitinib, compared with 5.7% and 4.4% in the respective placebo groups.
However, the results were considerably more modest when researchers examined patients achieving at least 75% improvement across the body.
In STOP-V1, only 2.6% of treated patients achieved this threshold, compared with 1.3% receiving placebo. The difference was not statistically significant.
In STOP-V2, 2.3% of treated patients achieved this level of improvement, compared with none in the placebo group. This difference was statistically significant, although the number of responders was small.
These results show that povorcitinib can improve whole-body pigmentation, but extensive repigmentation remained uncommon after one year.
Improvement Continued Throughout the Year
One potentially encouraging finding was that repigmentation continued to increase through week 52 without an obvious plateau.
This matters because restoring pigmentation is generally a gradual process.
Even after inflammatory activity is reduced, melanocytes need time to produce pigment and repopulate affected skin.
The continuing improvement raises the possibility that some patients could benefit from longer treatment.
However, the published results cannot establish how much additional repigmentation will occur beyond one year or whether pigmentation will remain after treatment stops.
The Drug May Also Help Stabilize Vitiligo
Restoring pigmentation is not the only potential goal of vitiligo treatment. For people whose white patches are spreading, preventing further pigment loss can also be important.
The STOP-V researchers conducted additional analyses to investigate whether povorcitinib helped stabilize the disease.
In STOP-V1, 94.3% of patients receiving povorcitinib had no worsening of their total-body vitiligo score after 52 weeks, compared with 71.8% receiving placebo.
In STOP-V2, the corresponding figures were 87.6% and 69.2%.
Researchers also examined whether patients developed new patches or experienced expansion of existing lesions.
In STOP-V1, 94.2% of treated patients had no new or expanding lesions, compared with 80.3% receiving placebo. In STOP-V2, the figures were 84.2% and 78.7%.
These results raise the possibility that povorcitinib may help limit disease progression in addition to promoting repigmentation.
However, these were post hoc analyses conducted after the original study design was established. They should be considered exploratory findings rather than definitive proof that the medication prevents vitiligo from spreading.
Further studies are needed to determine whether this potential benefit persists with longer treatment and after medication is discontinued.
Did Patients Notice an Improvement?
Clinical measurements are important, but patients may judge treatment success differently from researchers.
The STOP-V trials therefore included the Vitiligo Noticeability Scale, which asks patients how noticeable their vitiligo appears after treatment.
After 52 weeks, 15.1% of patients receiving povorcitinib in STOP-V1 reported that their facial vitiligo was much less noticeable or no longer noticeable, compared with 3.2% receiving placebo.
In STOP-V2, the corresponding percentages were 10.2% and 1.6%.
These differences were statistically significant, indicating that some patients experienced visible changes they considered meaningful.
However, improvements in appearance did not necessarily translate into substantial changes in psychological symptoms.
The researchers reported minimal changes in anxiety and depression scores measured using the Hospital Anxiety and Depression Scale.
This distinction matters because the emotional effects of vitiligo vary considerably between individuals. Successful treatment should take account of each patient’s personal goals and quality of life, not only changes in skin pigmentation.
How This Could Change Vitiligo Treatment
The most important development is the possibility of expanding treatment beyond medications applied directly to the skin.
For years, treatment has often depended on topical corticosteroids, topical calcineurin inhibitors, narrowband ultraviolet B phototherapy, and combinations of these approaches.
These treatments can help some patients, but results vary, and managing widespread disease may require considerable time and effort.
Povorcitinib offers a different approach: targeting immune activity throughout the body with a once-daily medication.
If its benefits and safety are confirmed through regulatory review and longer-term research, it could become another option for patients whose disease is extensive or insufficiently controlled by existing treatments.
However, it would not necessarily replace topical medications or phototherapy.
A systemic drug may be more appropriate for certain patients, while someone with a few small patches may reasonably prefer a localized treatment with less systemic exposure.
How Does Povorcitinib Compare With Existing Treatments?
Ruxolitinib Cream: An Established Targeted Treatment
An important advance occurred in 2022, when the US Food and Drug Administration approved ruxolitinib cream, marketed as Opzelura, for nonsegmental vitiligo in patients aged 12 years and older.
Ruxolitinib also targets JAK signaling, but it is applied directly to affected skin rather than taken orally.
Its approval followed two phase 3 trials involving 674 participants.
In those trials (Rosmarin et al., 2022), approximately 30% of patients using ruxolitinib cream achieved at least 75% facial repigmentation after 24 weeks, compared with approximately 7% to 11% receiving the inactive cream.
The treatment is intended for affected areas covering up to 10% of the body’s surface.
This makes it particularly relevant for patients with more localized disease.
It would be misleading to conclude that ruxolitinib cream is more effective than povorcitinib simply because the response percentages differ.
The trials enrolled different populations, used different treatment durations, and were not designed to compare the medications directly.
For patients, the key distinction is that ruxolitinib cream is an approved topical option, while povorcitinib is being investigated as a systemic treatment for more extensive disease.
What Other Vitiligo Treatments Are in Development?
Povorcitinib is not the only oral medication showing promise.
Several research programs are investigating whether controlling immune activity can improve repigmentation or prevent further pigment loss.
Upadacitinib: Another Oral JAK Inhibitor in Phase 3 Research
One of the most advanced candidates is upadacitinib, an oral JAK inhibitor already used for certain other inflammatory conditions.
In August 2026, The Lancet published results from two phase 3 trials known as Viti-Up.
The study (Passeron et al., 2026) included 614 adults and adolescents aged 12 years or older with nonsegmental vitiligo.
Participants received 15 milligrams of upadacitinib or placebo daily.
After 48 weeks, approximately 25% and 23% of treated participants in the respective trials achieved at least 75% facial repigmentation, compared with 6% and 7% receiving placebo.
At least 50% improvement in total-body vitiligo scores occurred in approximately 19% and 21% of treated participants, compared with 6% in each placebo group.
These findings provide additional evidence that oral JAK inhibition can improve pigmentation in people with extensive vitiligo.
However, upadacitinib and povorcitinib have not been directly compared in a randomized trial.
Differences in eligibility criteria, disease severity, study populations, and follow-up periods prevent reliable conclusions about which medication works better.
Ritlecitinib and Other Immune-Targeting Approaches
Ritlecitinib is another oral immune-modifying medication that has been investigated for vitiligo.
Earlier phase 2 research found evidence that it could help stabilize active lesions and promote repigmentation.
However, those findings are less definitive than completed phase 3 evidence and do not establish its place in routine vitiligo treatment.
Other research is examining how to improve responses to immune-targeting drugs, including whether combining them with controlled light therapy could accelerate repigmentation.
This is a particularly relevant question because suppressing the immune attack and restoring pigment are related but distinct processes.
A treatment may reduce ongoing melanocyte damage without producing rapid or complete pigment restoration.
Why Combination Treatments May Matter
One potential direction is combining an immune-targeting medication with narrowband ultraviolet B phototherapy.
Phototherapy can stimulate processes involved in melanocyte activity and repigmentation, while JAK inhibition targets inflammatory signaling.
The approaches may therefore complement one another.
However, the STOP-V trials did not establish that combining povorcitinib with phototherapy is more effective or safe than povorcitinib alone.
That question requires controlled clinical research.
What About Side Effects and Long-Term Safety?
Although povorcitinib improved pigmentation in both trials, its safety profile is particularly important because vitiligo is a chronic condition that may require prolonged treatment.
In STOP-V1, 68.7% of patients receiving povorcitinib experienced at least one treatment-emergent adverse event, compared with 63.7% receiving placebo.
In STOP-V2, the corresponding figures were 66.7% and 62.7%.
Commonly reported events included acne, nasopharyngitis, upper respiratory tract infections, headaches, and increased blood creatine phosphokinase (CPK), an enzyme that can rise following muscle exertion or injury.
Treatment-related adverse events were reported in 30.9% of povorcitinib-treated patients versus 21.4% receiving placebo in STOP-V1, and 33.3% versus 18.7% in STOP-V2.
Serious adverse events were relatively uncommon, occurring in 2.1% of both treatment groups in STOP-V1 and in 3.6% of povorcitinib-treated patients versus 3.1% receiving placebo in STOP-V2.
However, several potentially important safety events warrant attention.
Four patients receiving povorcitinib developed basal cell carcinoma, a type of skin cancer, compared with none receiving placebo. Investigators considered one of these cases related to treatment. Some affected patients had a history of skin cancer or previous phototherapy exposure.
In STOP-V2, one patient receiving povorcitinib experienced pulmonary embolism, deep vein thrombosis, and thrombosis involving a varicose vein.
Investigators considered these events treatment-related and discontinued the medication. The patient also had other risk factors, including rheumatoid arthritis, hypertension, smoking, and a history of varicose veins.
No major adverse cardiovascular events, tuberculosis cases, or deaths occurred during the 52-week placebo-controlled periods.
The researchers also reported no clinically meaningful overall trends in liver enzymes or hematologic measurements associated with povorcitinib treatment.
Nevertheless, these results do not establish the medication’s long-term safety.
JAK inhibitors as a class have been associated with serious infections, blood clots, malignancies, and cardiovascular complications in certain patient populations.
The risks of an individual medication may differ according to the drug, dose, treatment duration, and patient’s medical history.
Longer follow-up studies are therefore needed to clarify the potential risks of povorcitinib, particularly for people who may require years of treatment.
What Should Someone With Vitiligo Do Now?
For someone living with widespread or progressing vitiligo, the new research provides a reason for cautious optimism.
It does not mean that povorcitinib is an immediately available or appropriate treatment for every patient.
People interested in treatment can discuss several questions with a dermatologist experienced in managing vitiligo:
- Is my vitiligo active, stable, localized, or widespread?
- Would an approved topical treatment or phototherapy be appropriate for my situation?
- What degree of repigmentation is realistic, and how long might treatment take?
- Are there clinical trials for which I may be eligible?
- If systemic treatment becomes available, what medical history or risk factors would affect its suitability?
Patients should not discontinue an existing treatment or take a JAK inhibitor prescribed for another condition specifically to treat vitiligo without appropriate medical guidance.
For those whose vitiligo causes emotional distress, support can also be part of care. Dermatologists may help patients access counseling or other resources when needed.
Treatment success is not defined solely by how much pigmentation returns. A person’s comfort, confidence, and quality of life also matter.
Limitations of the New Research
The STOP-V trials provide strong evidence that povorcitinib can improve repigmentation in some adults with moderate-to-severe nonsegmental vitiligo. Both studies were randomized, double-blind, placebo-controlled, and conducted across multiple countries.
However, several limitations should be considered when interpreting the findings.
First, the published results cover 52 weeks of treatment. Because vitiligo is a chronic condition, longer follow-up is necessary to determine whether additional repigmentation occurs and whether improvements persist after treatment is stopped.
Second, fewer than one in five treated patients achieved the primary facial repigmentation endpoint. Substantial whole-body repigmentation was even less common.
Third, the studies enrolled adults with moderate-to-severe nonsegmental vitiligo. Their findings cannot automatically be extended to children, people with segmental vitiligo, or patients with limited disease.
Fourth, most participants were White, accounting for approximately 79% of STOP-V1 and 85% of STOP-V2. Although different skin types were represented, additional research may help clarify treatment responses across more diverse populations.
Fifth, approximately 82% to 83% of participants completed treatment during the 52-week placebo-controlled period. The researchers used statistical methods to account for missing outcome data, but incomplete follow-up remains relevant when interpreting the findings.
Sixth, uncommon or delayed adverse effects may not become apparent in trials involving several hundred treated patients over one year.
Finally, the studies did not directly compare povorcitinib with ruxolitinib cream, phototherapy, or other investigational oral medications.
The ongoing extension periods are expected to provide additional information about longer-term effectiveness and safety.
Final Thoughts
The latest povorcitinib trials represent an important step in the development of treatments for widespread vitiligo.
Several late-stage research programs are now producing evidence that oral immune-targeting medications can restore pigmentation in some people with moderate-to-severe disease.
Povorcitinib achieved statistically significant facial and body repigmentation in two independent phase 3 trials. Exploratory findings also raise the possibility that it could help stabilize disease, an important goal for patients whose patches continue to spread.
Recent upadacitinib research has produced encouraging results using a similar treatment strategy.
These developments could eventually expand the choices available to patients who have struggled with limited or inconvenient treatment options.
However, meaningful repigmentation remains difficult to achieve, and systemic medications carry risks that must be weighed against their benefits.
The most encouraging message is not that vitiligo has been cured, but that researchers are developing a clearer understanding of how to interrupt the immune processes responsible for pigment loss.
For people living with vitiligo, that progress may translate into more personalized and effective treatment options in the years ahead.
Funding and Disclosures
The STOP-V1 and STOP-V2 clinical trials were funded by Incyte Corporation, the company developing povorcitinib.
According to the funding statement published in Nature Medicine, the sponsor participated in study design, data collection, data analysis, interpretation of results, manuscript preparation, and the decision to publish, in collaboration with the study authors.
Several investigators reported financial relationships with pharmaceutical companies, including Incyte.
The ruxolitinib cream trials were funded by Incyte, while the upadacitinib Viti-Up trials were funded by AbbVie.
These disclosures are important when evaluating industry-sponsored clinical research. However, commercial funding does not automatically invalidate study findings.
The randomized, double-blind, placebo-controlled designs of the STOP-V trials provide meaningful evidence of treatment effectiveness, while independent evaluation and longer-term safety monitoring remain important.
References
Ezzedine, K., Lui, H., Eleftheriadou, V., Desai, S. R., Passeron, T., Ringuet, J., van Geel, N., Wolkerstorfer, A., Lynde, C., Augustin, M., López-Estebaranz, J. L., Grimes, P., Rosmarin, D., Brown, K., Wei, S., Karanam, S., Kornacki, D., & Pandya, A. G. (2026). Povorcitinib for nonsegmental vitiligo: Two randomized, controlled, phase 3 STOP-V trials. Nature Medicine. https://doi.org/10.1038/s41591-026-04739-2
Passeron, T., Prajapati, V. H., Sivamani, R. K., Ezzedine, K., van Geel, N., Hamzavi, I., Pandya, A. G., Rosmarin, D., Xiang, L., Suzuki, T., Desai, S., Rashighi, M., Suravaram, S., Fish, I., Hu, X., Wu, X., Wang, M., Yu, Y., Soliman, A. M., . . . Seneschal, J. (2026). Efficacy and safety of upadacitinib in adults and adolescents for treatment of non-segmental vitiligo (Viti-Up): Results of two phase 3 randomised controlled studies. The Lancet, 408(10555), 636–648. https://doi.org/10.1016/S0140-6736(26)00896-2
Rosmarin, D., Passeron, T., Pandya, A. G., Grimes, P., Harris, J. E., Desai, S. R., Lebwohl, M., Ruer-Mulard, M., Seneschal, J., Wolkerstorfer, A., Kornacki, D., Sun, K., Butler, K., & Ezzedine, K. (2022). Two phase 3, randomized, controlled trials of ruxolitinib cream for vitiligo. The New England Journal of Medicine, 387(16), 1445–1455. https://doi.org/10.1056/NEJMoa2118828
